Cyteir Therapeutics, Inc.
CIK 0001662244
Revenue (TTM)
—
Q3 Sep 2023
Net Income (TTM)
−$35.47M
−9.3% YoY
Q3 Sep 2023
EPS Diluted (TTM)
−$1.00
+39.4% YoY
Q3 Sep 2023
Gross Margin
—
Q3 Sep 2023
Operating Margin
—
Q3 Sep 2023
Net Margin
—
Q3 Sep 2023
Free Cash Flow (TTM)
−$42.84M
Q3 Sep 2023
Cash
$129.24M
Q3 Sep 2023
Total Debt
—
Q3 Sep 2023
Shares Outstanding
36M sh
Q3 Sep 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.